

Luis Puig

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/518218/publications.pdf>

Version: 2024-02-01

497
papers

19,525
citations

17440

63
h-index

18647

119
g-index

526
all docs

526
docs citations

526
times ranked

13214
citing authors

#	ARTICLE	IF	CITATIONS
1	Secukinumab in Plaque Psoriasis – Results of Two Phase 3 Trials. <i>New England Journal of Medicine</i> , 2014, 371, 326-338.	27.0	1,675
2	Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. <i>Lancet, The</i> , 2013, 382, 780-789.	13.7	688
3	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. <i>New England Journal of Medicine</i> , 2015, 373, 1318-1328.	27.0	656
4	Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 990-999.	0.9	576
5	Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions. <i>Journal of Investigative Dermatology</i> , 2010, 130, 1785-1796.	0.7	554
6	Epidemiology of atopic dermatitis in adults: Results from an international survey. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1284-1293.	5.7	546
7	Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. <i>Lancet, The</i> , 2018, 392, 650-661.	13.7	457
8	Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 871-881.e30.	1.2	423
9	Development and validation of the International Hidradenitis Suppurativa Severity Score System (I-HSS). <i>Journal of the American Academy of Dermatology</i> , 2017, 177, 1401-1409.	1.5	301
10	European consensus statement on phenotypes of pustular psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1792-1799.	2.4	269
11	Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. <i>British Journal of Dermatology</i> , 2018, 178, 114-123.	1.5	269
12	Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1000-1006.	0.9	255
13	<i>Candida</i> infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. <i>British Journal of Dermatology</i> , 2017, 177, 47-62.	1.5	218
14	Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. <i>Autoimmunity Reviews</i> , 2020, 19, 102429.	5.8	197
15	Actinic keratosis with atypical basal cells (AKI) is the most common lesion associated with invasive squamous cell carcinoma of the skin. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 991-997.	2.4	188
16	The role of IL-23 and the IL-23/Th17 immune axis in the pathogenesis and treatment of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1616-1626.	2.4	187
17	Comparison of Biologics and Oral Treatments for Plaque Psoriasis. <i>JAMA Dermatology</i> , 2020, 156, 258.	4.1	169
18	Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 1007-1011.	2.4	166

#	ARTICLE	IF	CITATIONS
19	Clinical and genetic differences between pustular psoriasis subtypes. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1021-1026.	2.9	165
20	Multiplex PCR of sonication fluid accurately differentiates between prosthetic joint infection and aseptic failure. <i>Journal of Infection</i> , 2012, 65, 541-548.	3.3	155
21	<scp>PASI</scp>90 response: the new standard in therapeutic efficacy for psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 645-648.	2.4	150
22	Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2002-2010.	2.4	139
23	Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry-based study. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 60-71.	2.9	136
24	Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1984-1988.	0.9	131
25	A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 438-453.	2.4	122
26	Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 117-122.	1.2	120
27	Seroprevalence of <i>Trypanosoma cruzi</i> infection in at-risk blood donors in Catalonia (Spain). <i>Transfusion</i> , 2008, 48, 1862-1868.	1.6	119
28	Inflammatory, immune-mediated adverse reactions related to soft tissue dermal fillers. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 241-258.	3.4	116
29	The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 541-554.	1.3	112
30	The role of IL 23 in the treatment of psoriasis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 525-534.	3.0	111
31	Advantages of sonication fluid culture for the diagnosis of prosthetic joint infection. <i>Journal of Infection</i> , 2014, 69, 35-41.	3.3	108
32	ACUTE FEBRILE NEUTROPHILIC DERMATOSIS (SWEET'S SYNDROME). <i>International Journal of Dermatology</i> , 1993, 32, 261-268.	1.0	106
33	Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 1387-1404.	2.4	105
34	Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1-18.	2.4	105
35	Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks. <i>British Journal of Dermatology</i> , 2020, 182, 605-617.	1.5	103
36	Late-Onset Inflammatory Adverse Reactions Related to Soft Tissue Filler Injections. <i>Clinical Reviews in Allergy and Immunology</i> , 2013, 45, 97-108.	6.5	102

#	ARTICLE	IF	CITATIONS
37	JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors. <i>Drugs</i> , 2020, 80, 341-352.	10.9	101
38	Risk Factors for Degree and Type of Sequelae After Involution of Untreated Hemangiomas of Infancy. <i>JAMA Dermatology</i> , 2016, 152, 1239.	4.1	99
39	Pityriasis lichenoides in children: clinicopathologic review of 22 patients.. <i>Pediatric Dermatology</i> , 1998, 15, 1-6.	0.9	98
40	Urine metabolome profiling of immune-mediated inflammatory diseases. <i>BMC Medicine</i> , 2016, 14, 133.	5.5	97
41	Documento de consenso sobre la evaluación y el tratamiento de la psoriasis moderada/grave del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología. <i>Actas Dermo-sifiligráficas</i> , 2009, 100, 277-286.	0.4	95
42	Prosthesis Failure Within 2 Years of Implantation Is Highly Predictive of Infection. <i>Clinical Orthopaedics and Related Research</i> , 2013, 471, 3672-3678.	1.5	93
43	Sonication versus Vortexing of Implants for Diagnosis of Prosthetic Joint Infection. <i>Journal of Clinical Microbiology</i> , 2013, 51, 591-594.	3.9	92
44	Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 58.	4.1	90
45	Factors affecting meniscal extrusion: correlation with MRI, clinical, and arthroscopic findings. <i>Knee Surgery, Sports Traumatology, Arthroscopy</i> , 2006, 14, 394-398.	4.2	87
46	Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial. <i>Arthritis Care and Research</i> , 2015, 67, 1739-1749.	3.4	87
47	Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. <i>British Journal of Dermatology</i> , 2013, 168, 609-616.	1.5	85
48	Expression profiles associated with aggressive behavior in Merkel cell carcinoma. <i>Modern Pathology</i> , 2007, 20, 90-101.	5.5	84
49	Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent. <i>BioDrugs</i> , 2018, 32, 397-404.	4.6	82
50	Review of 26 cases of classical pyoderma gangrenosum: clinical and therapeutic features. <i>Journal of Dermatological Treatment</i> , 2004, 15, 146-152.	2.2	80
51	Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others. <i>Current Problems in Dermatology</i> , 2018, 53, 49-63.	0.7	80
52	Scalp psoriasis: European consensus on grading and treatment algorithm. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 1435-1444.	2.4	79
53	Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes. <i>Human Molecular Genetics</i> , 2012, 21, 4549-4557.	2.9	79
54	Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 70-79.e3.	1.2	77

#	ARTICLE	IF	CITATIONS
55	Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. <i>Hepatology</i> , 2001, 34, 1035-1040.	7.3	74
56	Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biológicos. <i>Actas Dermo-sifiligráficas</i> , 2009, 100, 386-413.	0.4	73
57	Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. <i>Journal of Dermatological Treatment</i> , 2020, 31, 606-614.	2.2	72
58	Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants. <i>Pediatric Allergy and Immunology</i> , 2015, 26, 306-315.	2.6	71
59	Ustekinumab Treatment of TNF Antagonist-Induced Paradoxical Psoriasis Flare in a Patient with Psoriatic Arthritis: Case Report and Review. <i>Dermatology</i> , 2012, 225, 14-17.	2.1	68
60	Therapy of paraneoplastic pemphigus with Rituximab: a case report and review of literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006, 20, 69-74.	2.4	66
61	Metotrexato: guía de uso en psoriasis. <i>Actas Dermo-sifiligráficas</i> , 2010, 101, 600-613.	0.4	65
62	Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1633-1653.	2.4	65
63	ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 1066-1072.	1.2	65
64	Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 567-579.	6.7	65
65	Treatment of Psoriasis with Anti-TNF Drugs during Pregnancy: Case Report and Review of the Literature. <i>Dermatology</i> , 2010, 220, 71-76.	2.1	64
66	Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 23-32.	6.7	64
67	Leishmania and HIV co-infection: dermatological manifestations. <i>Annals of Tropical Medicine and Parasitology</i> , 2003, 97, 107-114.	1.6	63
68	Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 213-220.	2.4	60
69	Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 307-311.	6.7	60
70	The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). <i>Journal of Dermatological Treatment</i> , 2013, 24, 169-178.	2.2	59
71	Grover Disease: A Reappraisal of Histopathological Diagnostic Criteria in 120 Cases. <i>American Journal of Dermatopathology</i> , 2010, 32, 541-549.	0.6	58
72	Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain. <i>Journal of Dermatological Treatment</i> , 2019, 30, 424-429.	2.2	57

#	ARTICLE	IF	CITATIONS
73	Multinucleate cell angiohistiocytoma: a fibrohistiocytic proliferation with increased mast cell numbers and vascular hyperplasia. <i>Journal of Cutaneous Pathology</i> , 2002, 29, 232-237.	1.3	56
74	Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparatorâ€“controlled phase 3 AMAGINE-2 trial. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 352-359.	1.2	56
75	Treatment Options and Goals for Patients with Generalized Pustular Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 51-64.	6.7	56
76	Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 824-830.e2.	1.2	55
77	Epidermal Cellâ€™Polymorphonuclear Leukocyte Cooperation in the Formation of Leukotriene B4 by Transcellular Biosynthesis. <i>Journal of Investigative Dermatology</i> , 1992, 98, 333-339.	0.7	54
78	Consensus Statement on the Safety Profile of Topical Calcineurin Inhibitors. <i>Dermatology</i> , 2005, 211, 77-78.	2.1	54
79	Enzymeâ€™linked immunosorbent assay (ELISA) and indirect immunofluorescence testing in a bullous pemphigoid and pemphigoid gestationis. <i>International Journal of Dermatology</i> , 2008, 47, 1245-1249.	1.0	53
80	Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis. <i>British Journal of Dermatology</i> , 2013, 168, 820-824.	1.5	52
81	The patientâ€™reported disease burden in adults with atopic dermatitis: a crossâ€™sectional study in Europe and Canada. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1026-1036.	2.4	52
82	Prevalence of most common skin diseases in Europe: a populationâ€™based study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1088-1096.	2.4	52
83	Initial results of ixekizumab efficacy and safety in realâ€™world plaque psoriasis patients: a multicentre retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 553-559.	2.4	51
84	Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. <i>Dermatology and Therapy</i> , 2020, 10, 133-150.	3.0	51
85	Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper. <i>Journal of Dermatological Treatment</i> , 2015, 26, 103-112.	2.2	50
86	Imatinib-associated lichenoid eruption: acitretin treatment allows maintained antineoplastic effect. <i>British Journal of Dermatology</i> , 2006, 154, 1213-1216.	1.5	49
87	Treatment Adherence Intervention Studies in Dermatology and Guidance on How to Support Adherence. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 253-271.	6.7	49
88	Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. <i>British Journal of Dermatology</i> , 2017, 177, 1495-1502.	1.5	48
89	Benign Myoepithelioma of the Skin. <i>American Journal of Dermatopathology</i> , 1998, 20, 208-212.	0.6	48
90	Pathophysiology of Generalized Pustular Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 13-19.	6.7	48

#	ARTICLE	IF	CITATIONS
91	Topical tacrolimus 0.1% ointment (ProtopicR) reverses nickel contact dermatitis elicited by allergen challenge to a similar degree to mometasone furoate 0.1% with greater suppression of late erythema. <i>Contact Dermatitis</i> , 2003, 49, 185-188.	1.4	47
92	Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patients. <i>British Journal of Dermatology</i> , 2005, 153, 417-423.	1.5	47
93	Onset of flexural psoriasis during infliximab treatment for Crohn's disease. <i>Clinical and Experimental Dermatology</i> , 2005, 30, 713-714.	1.3	47
94	Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre. <i>British Journal of Dermatology</i> , 2013, 169, 1141-1147.	1.5	46
95	Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltimMa1 and UltimMa2 studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2830-2838.	2.4	46
96	Brooke-Spiegler Syndrome Variant Segregation of Tumor Types with Mixed Differentiation in Two Generations. <i>American Journal of Dermatopathology</i> , 1998, 20, 56-60.	0.6	46
97	Treatment of Acrodermatitis Continua of Hallopeau with TNF-Blocking Agents: Case Report and Review. <i>Dermatology</i> , 2010, 220, 154-158.	2.1	44
98	Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. <i>Journal of Dermatological Treatment</i> , 2017, 28, 492-499.	2.2	44
99	Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 355-364.	0.9	44
100	Adherencia y satisfacción del paciente y características organolépticas y de uso de los tratamientos tópicos utilizados para la psoriasis: Consenso Delphi del panel de expertos y miembros del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología. <i>Actas Dermo-sifiliográficas</i> , 2013, 104, 488-496.	0.4	43
101	Treatment goals for psoriasis: Should PASI 90 become the standard of care?. <i>Actas Dermo-sifiliográficas</i> , 2015, 106, 155-157.	0.4	43
102	Systemic methotrexate for the treatment of psoriasis. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 553-563.	3.0	43
103	Cutibacterium acnes in primary reverse shoulder arthroplasty: from skin to deep layers. <i>Journal of Shoulder and Elbow Surgery</i> , 2019, 28, 839-846.	2.6	43
104	Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4344.	4.1	43
105	Nomenclature and clinical phenotypes of atopic dermatitis. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110029.	2.5	43
106	Merkel cell (primary neuroendocrine) carcinoma of the skin with nodal metastasis showing rhabdomyosarcomatous differentiation. <i>Journal of Cutaneous Pathology</i> , 2002, 29, 619-622.	1.3	41
107	Prognostic significance of p27Kip1, p45Skp2 and Ki67 expression profiles in Merkel cell carcinoma, extracutaneous small cell carcinoma, and cutaneous squamous cell carcinoma. <i>Histopathology</i> , 2005, 46, 614-621.	2.9	41
108	Brodalumab: The first anti-IL-17 receptor agent for psoriasis. <i>Drugs of Today</i> , 2017, 53, 283.	1.1	41

#	ARTICLE	IF	CITATIONS
109	Bortezomib-associated cutaneous vasculitis. <i>British Journal of Dermatology</i> , 2007, 157, 799-801.	1.5	40
110	Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. <i>Dermatology and Therapy</i> , 2021, 11, 885-905.	3.0	40
111	Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1156-1161.	1.2	39
112	Vascular Stains: Proposal for a Clinical Classification to Improve Diagnosis and Management. <i>Pediatric Dermatology</i> , 2016, 33, 570-584.	0.9	39
113	Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. <i>Journal of Dermatological Treatment</i> , 2018, 29, 334-346.	2.2	39
114	Biosimilars for psoriasis: preclinical analytical assessment to determine similarity. <i>British Journal of Dermatology</i> , 2016, 174, 282-286.	1.5	38
115	Lipstick allergic contact dermatitis from gallates. <i>Contact Dermatitis</i> , 1995, 32, 359-360.	1.4	37
116	Over-Expression of p45SKP2 in Kaposi's Sarcoma Correlates with Higher Tumor Stage and Extracutaneous Involvement but Is Not Directly Related to p27KIP1 Down-Regulation. <i>Modern Pathology</i> , 2002, 15, 1227-1235.	5.5	37
117	One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the <scp>TRANSIT</scp> randomized trial in moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2014, 170, 435-444.	1.5	37
118	Discapacidad acumulada en el transcurso vital: la cicatriz de la psoriasis en la vida del paciente. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 128-134.	0.4	37
119	Metotrexato en psoriasis moderada-grave: revisión de la literatura y recomendaciones de experto. <i>Actas Dermo-sifiliográficas</i> , 2016, 107, 194-206.	0.4	37
120	Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study. <i>British Journal of Dermatology</i> , 2017, 176, 1195-1203.	1.5	37
121	REITER'S SYNDROME-LIKE PATTERN IN AIDS-ASSOCIATED PSORIASIFORM DERMATITIS. <i>International Journal of Dermatology</i> , 1996, 35, 484-488.	1.0	36
122	Psoriasis beyond the skin: an expert group consensus on the management of psoriatic arthritis and common comorbidities in patients with moderate-to-severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1661-1669.	2.4	36
123	Psoriasis: bases genéticas y patogénicas. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 535-545.	0.4	36
124	A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP). <i>British Journal of Dermatology</i> , 2017, 177, 197-205.	1.5	36
125	Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study. <i>Archives of Dermatological Research</i> , 2019, 311, 421-424.	1.9	36
126	Thrombotic thrombocytopenic purpura and pregnancy: a review of ten cases. <i>Vox Sanguinis</i> , 2004, 87, 287-290.	1.5	35

#	ARTICLE	IF	CITATIONS
127	Long-Term Efficacy, Safety and Drug Survival of Ustekinumab in a Spanish Cohort of Patients with Moderate to Severe Plaque Psoriasis. <i>Dermatology</i> , 2015, 230, 46-54.	2.1	35
128	Successful treatment of oral erosive lichen planus with mycophenolate mofetil. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007, 21, 259-60.	2.4	34
129	Occurrence of Hepoxilins and Trioxilins in Psoriatic Lesions. <i>Journal of Investigative Dermatology</i> , 1998, 110, 303-310.	0.7	33
130	Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis. <i>International Journal of Dermatology</i> , 2004, 43, 978-983.	1.0	33
131	Juvenile psoriasis and its clinical management: a European expert group consensus. <i>JDDG - Journal of the German Society of Dermatology</i> , 2010, 8, 812-818.	0.8	33
132	The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1196-1207.	2.4	33
133	Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials. <i>British Journal of Dermatology</i> , 2019, 180, 67-75.	1.5	33
134	Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. <i>British Journal of Dermatology</i> , 2020, 182, 304-315.	1.5	33
135	A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents. <i>JAMA Dermatology</i> , 2020, 156, 384.	4.1	33
136	Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 827-834.	1.2	33
137	Ustekinumab in clinical practice: response depends on dose and previous treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 508-513.	2.4	32
138	Spanish Evidence-Based Guidelines on the Treatment of Psoriasis With Biologic Agents, 2013. Part 1: On Efficacy and Choice of Treatment. <i>Actas Dermo-sifiligráficas</i> , 2013, 104, 694-709.	0.4	32
139	Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis. <i>Journal of Dermatological Treatment</i> , 2015, 26, 7-15.	2.2	32
140	The biological basis of disease recurrence in psoriasis: a historical perspective and current models. <i>British Journal of Dermatology</i> , 2022, 186, 773-781.	1.5	32
141	Epidermal expression of 65 and 72 kd heat shock proteins in psoriasis and AIDS-associated psoriasiform dermatitis. <i>Journal of the American Academy of Dermatology</i> , 1995, 33, 985-989.	1.2	31
142	Isotretinoin Treatment of Acne in a Patient with Apert Syndrome. <i>Pediatric Dermatology</i> , 2003, 20, 443-446.	0.9	31
143	Long-term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1514-1521.	2.4	31
144	Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 224-231.	2.4	31

#	ARTICLE	IF	CITATIONS
145	GCAT Genomes for life: a prospective cohort study of the genomes of Catalonia. <i>BMJ Open</i> , 2018, 8, e018324.	1.9	31
146	Sti571-induced Stevens-Johnson Syndrome. <i>British Journal of Haematology</i> , 2002, 119, 274-275.	2.5	30
147	Clinical Management of Atopic Eczema with Pimecrolimus Cream 1% (Elidel®) in Paediatric Patients. <i>Dermatology</i> , 2007, 215, 3-17.	2.1	30
148	Psoriasis beyond the skin: a review of the literature on cardiometabolic and psychological co-morbidities of psoriasis. <i>European Journal of Dermatology</i> , 2014, 24, 305-311.	0.6	30
149	Metotrexato: novedades terapéuticas. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 583-589.	0.4	30
150	Biosimilars for the treatment of psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 993-1000.	3.1	30
151	Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. <i>Dermatology and Therapy</i> , 2022, 12, 495-510.	3.0	30
152	Allergic contact dermatitis due to ranitidine. <i>Contact Dermatitis</i> , 1987, 17, 54-55.	1.4	29
153	Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3). <i>American Journal of Clinical Dermatology</i> , 2017, 18, 273-280.	6.7	29
154	Topical Timolol for Paronychia and Pseudopyogenic Granuloma in Patients Treated With Epidermal Growth Factor Receptor Inhibitors and Capecitabine. <i>JAMA Dermatology</i> , 2018, 154, 99.	4.1	29
155	Erythema Gyratum Atrophicans Transiens Neonatale: A Variant of Cutaneous Neonatal Lupus Erythematosus. <i>Pediatric Dermatology</i> , 1988, 5, 112-116.	0.9	28
156	Carbamazepine-induced drug rashes: diagnostic value of patch tests depends on clinico-pathologic presentation. <i>Contact Dermatitis</i> , 1996, 34, 435-437.	1.4	28
157	Acantholytic dyskeratotic naevi following Blaschko's lines: a mosaic form of Darier's disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2003, 17, 196-199.	2.4	28
158	Acute Severe Methotrexate Toxicity in Patients with Psoriasis: A Case Series and Discussion. <i>Dermatology</i> , 2014, 229, 306-309.	2.1	28
159	Efficacy and Safety of Topical Timolol for the Treatment of Infantile Hemangioma in the Early Proliferative Stage. <i>JAMA Dermatology</i> , 2021, 157, 583.	4.1	28
160	Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMItless open-label extension trial beyond 3 years of follow-up. <i>British Journal of Dermatology</i> , 2021, 185, 1135-1145.	1.5	28
161	Pigmented epidermotropic ductal carcinoma of the breast in a male. Ultrastructural evidence of melanocytic colonization and melanin transfer to the tumor. <i>Journal of Cutaneous Pathology</i> , 1995, 22, 276-280.	1.3	27
162	Directrices del grupo español de psoriasis (GEP) basadas en la evidencia para el uso de medicamentos biológicos en pacientes con psoriasis en localizaciones de difícil tratamiento (uñas, cuero cabelludo). <i>TJ ETQ</i> 0004rgBT / Overlock 10		

#	ARTICLE	IF	CITATIONS
163	Enfermedades inflamatorias mediadas por inmunidad y otras comorbilidades en pacientes con psoriasis. Características basales de la cohorte de pacientes con psoriasis del estudio AQUILES. Actas Dermo-sifiliográficas, 2015, 106, 35-43.	0.4	27
164	Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic Arthritis. Arthritis Care and Research, 2016, 68, 1812-1822.	3.4	27
165	Genome-Wide Pathway Analysis Identifies Genetic Pathways Associated with Psoriasis. Journal of Investigative Dermatology, 2016, 136, 593-602.	0.7	27
166	Proliferating trichilemmal tumour: p53 immunoreactivity in association with p27Kip1 over-expression indicates a low-grade carcinoma profile. Histopathology, 2001, 38, 454-457.	2.9	26
167	The Pathogenesis and Genetics of Psoriasis. Actas Dermo-sifiliográficas, 2014, 105, 535-545.	0.4	26
168	Dual inhibition of IL-17A and IL-17F in psoriatic disease. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232110378.	2.5	26
169	Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey*. British Journal of Dermatology, 2021, 185, 80-90.	1.5	26
170	New perspectives on the treatment of hidradenitis suppurativa. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232110559.	2.5	26
171	ERYTHEMA MULTIFORME-LIKE REACTION FOLLOWING DIPENCYPRONE TREATMENT OF PLANE WARTS. International Journal of Dermatology, 1994, 33, 201-203.	1.0	25
172	Efficacy in reducing potassium load in irradiated red cell bags with a potassium adsorption filter. Transfusion, 2008, 48, 1966-1970.	1.6	25
173	Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study. European Journal of Dermatology, 2012, 22, 762-769.	0.6	25
174	Propranolol-resistant infantile hemangioma successfully treated with sirolimus. Pediatric Dermatology, 2020, 37, 684-686.	0.9	25
175	Calcinosis cutis following calcium chloride electrode paste application for auditory-brainstem evoked potentials recording.. Pediatric Dermatology, 1998, 15, 27-30.	0.9	25
176	Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa. Journal of the American Academy of Dermatology, 2005, 53, 62-66.	1.2	24
177	Conventional and molecular diagnostic strategies for prosthetic joint infections. Expert Review of Molecular Diagnostics, 2014, 14, 83-96.	3.1	24
178	Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT). British Journal of Dermatology, 2014, 170, 425-434.	1.5	24
179	Elaboración mediante el método Delphi de recomendaciones para el manejo coordinado (reumatólogo/dermatólogo) de la artritis psoriásica. Actas Dermo-sifiliográficas, 2014, 105, 216-232.	0.4	24
180	Epithelial-to-mesenchymal transition contributes to invasion in squamous cell carcinomas originated from actinic keratosis through the differentiated pathway, whereas proliferation plays a more significant role in the classical pathway. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 581-586.	2.4	24

#	ARTICLE	IF	CITATIONS
181	Pilonidal sinus disease: an intergluteal localization of Hidradenitis suppurativa/acne inversa: a cross-sectional study among 2465 patients. <i>British Journal of Dermatology</i> , 2019, 181, 1198-1206.	1.5	24
182	Cyclooxygenase Activity Is Increased in Platelets from Psoriatic Patients. <i>Journal of Investigative Dermatology</i> , 1991, 97, 922-926.	0.7	23
183	Inflammation of actinic keratoses and acral erythrodysesthesia during capecitabine treatment. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, S119-S120.	1.2	23
184	Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials. <i>Advances in Therapy</i> , 2017, 34, 1327-1339.	2.9	23
185	The safety of ustekinumab for the treatment of psoriatic arthritis. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 733-742.	2.4	23
186	Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial. <i>Dermatology and Therapy</i> , 2021, 11, 1319-1332.	3.0	23
187	Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes. <i>Acta Dermato-Venereologica</i> , 2019, 99, 971-977.	1.3	23
188	Photoallergic contact dermatitis caused by benzophenones in magazine inks. <i>Contact Dermatitis</i> , 2013, 69, 124-126.	1.4	22
189	Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 741-748.	1.2	22
190	Body dysmorphic disorder in patients with acne: a multicentre study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 370-376.	2.4	22
191	Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1744-1749.	2.4	22
192	Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis. <i>Dermatology and Therapy</i> , 2022, 12, 167-184.	3.0	22
193	Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis. <i>Pharmacogenomics Journal</i> , 2015, 15, 322-325.	2.0	21
194	Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis: A Model-Based Meta-Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 1006-1016.	4.7	21
195	Subclinical enthesopathy of extensor digitorum tendon is highly prevalent and associated with clinical and ultrasound alterations of the adjacent fingernails in patients with psoriatic disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1728-1736.	2.4	21
196	Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension. <i>Acta Dermato-Venereologica</i> , 2018, 98, 98-102.	1.3	21
197	Cutaneous extramedullary hematopoiesis in a patient with acute myelofibrosis. <i>Archives of Dermatology</i> , 1988, 124, 329-331.	1.4	21
198	Juvenile Psoriasis und ihre Behandlungsmöglichkeiten: Konsensus einer europäischen Expertengruppe. <i>JDDG - Journal of the German Society of Dermatology</i> , 2010, 8, 812-819.	0.8	20

#	ARTICLE	IF	CITATIONS
199	Riesgo cardiovascular y psoriasis: papel de la terapia biol3gica. Actas Dermo-sifiliogr3ficas, 2012, 103, 853-862.	0.4	20
200	Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV , multicenter, randomized, controlled, prospective study. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1156-1163.	2.4	20
201	Secukinumab (AIN457) for the treatment of psoriasis. Expert Review of Clinical Immunology, 2015, 11, 1177-1188.	3.0	20
202	Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial. Journal of Dermatological Treatment, 2019, 30, 27-34.	2.2	20
203	Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. Journal of Dermatological Treatment, 2022, 33, 1652-1660.	2.2	20
204	Psoriasis and Mental Health Workshop Report: Exploring the Links between Psychosocial Factors, Psoriasis, Neuroinflammation and Cardiovascular Disease Risk. Acta Dermato-Venereologica, 2020, 100, 1-8.	1.3	20
205	Psoriasis Induced by Ophthalmic Timolol Preparations. American Journal of Ophthalmology, 1989, 108, 455-456.	3.3	19
206	Erythema-multiforme-like eruption due to topical contactants: expression of adhesion molecules and their ligands and characterization of the infiltrate. Contact Dermatitis, 1995, 33, 329-352.	1.4	19
207	Photocontact dermatitis due to dexketoprofen. Contact Dermatitis, 2002, 47, 237-237.	1.4	19
208	Hepoxilin B3 and its Enzymatically Formed Derivative Trioxilin B3 are Incorporated into Phospholipids in Psoriatic Lesions. Journal of Investigative Dermatology, 2002, 118, 139-146.	0.7	19
209	Validation of a new tool to assess health-related quality of life in psoriasis: the PSO-LIFE questionnaire. Health and Quality of Life Outcomes, 2012, 10, 56.	2.4	19
210	Adherence and Patient Satisfaction With Topical Treatment in Psoriasis, and the Use, and Organoleptic Properties of Such Treatments: A Delphi Study With an Expert Panel and Members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermo-sifiliogr3ficas, 2013, 104, 488-496.	0.4	19
211	Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: The VACAP study. Actas Dermo-sifiliogr3ficas, 2013, 104, 807-814.	0.4	19
212	Tratamiento de la psoriasis en placas moderada a grave con fármacos biol3gicos: an3lisis del sobrecoste de la intensificaci3n temporal frente a cambio a otro biol3gico en caso de fracaso secundario. Actas Dermo-sifiliogr3ficas, 2014, 105, 401-412.	0.4	19
213	CD44 and melanocytic tumors: a possible role for standard CD44 in the epidermotropic spread of melanoma. Journal of Cutaneous Pathology, 1996, 23, 133-139.	1.3	18
214	A deletion atADAMTS9-MAG11locus is associated with psoriatic arthritis risk. Annals of the Rheumatic Diseases, 2015, 74, 1875-1881.	0.9	18
215	Describing the burden of the COVID19 pandemic in people with psoriasis: findings from a global cross-sectional study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e636-e640.	2.4	18
216	Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey. Dermatology and Therapy, 2022, 12, 61-78.	3.0	18

#	ARTICLE	IF	CITATIONS
217	Of APACHEs and PALEFACEs. American Journal of Dermatopathology, 1995, 17, 209.	0.6	17
218	ID REACTION TO MOLLUSCUM CONTAGIOSUM. Pediatric Dermatology, 1996, 13, 349-350.	0.9	17
219	Quantitative and qualitative analysis of proteins in fresh frozen plasma obtained from whole blood donations and prepared with two photochemical treatments. Transfusion and Apheresis Science, 2008, 39, 115-121.	1.0	17
220	Psoriasis y embarazo: revisi3n (i). Actas Dermo-sifilogr4ficas, 2014, 105, 734-743.	0.4	17
221	Treatment of psoriasis with etanercept: the typical patient profile. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1092-1099.	2.4	17
222	Results of cement spacer sonication in the second stage of two-stage treatment of shoulder arthroplasty infection. Journal of Orthopaedic Surgery and Research, 2018, 13, 58.	2.3	17
223	Adjusted treatment COMPARisons between guselkumab and ustekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS analysis. British Journal of Dermatology, 2020, 183, 276-284.	1.5	17
224	Real-world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis. British Journal of Dermatology, 2021, 185, 660-662.	1.5	17
225	Adams-Oliver syndrome with unusual central nervous system alterations.. Pediatric Dermatology, 1998, 15, 48-50.	0.9	17
226	Dermatomyositis-like eruption following hydroxyurea therapy. Journal of the European Academy of Dermatology and Venereology, 2000, 14, 227-228.	2.4	16
227	Hypomelanosis of Ito with Sturge-Weber Syndrome-like Leptomeningeal Angiomas. Pediatric Dermatology, 2002, 19, 536-540.	0.9	16
228	Methotrexate: New Therapeutic Approaches. Actas Dermo-sifilogr4ficas, 2014, 105, 583-589.	0.4	16
229	Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment. Journal of Dermatological Treatment, 2014, 25, 470-481.	2.2	16
230	Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health Service. Journal of Dermatological Treatment, 2017, 28, 623-630.	2.2	16
231	Biosimilars for psoriasis: clinical studies to determine similarity. British Journal of Dermatology, 2017, 177, 23-33.	1.5	16
232	Reversibility of alopecia with effective treatment of moderate-to-severe psoriasis: longitudinal data from the EPIDEPSO study. British Journal of Dermatology, 2019, 180, 397-403.	1.5	16
233	The safety of brodalumab for the treatment of psoriasis. Expert Opinion on Drug Safety, 2020, 19, 365-372.	2.4	16
234	Therapeutic targeting of the IL-13 pathway in skin inflammation. Expert Review of Clinical Immunology, 2021, 17, 15-25.	3.0	16

#	ARTICLE	IF	CITATIONS
235	From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6740.	4.1	16
236	Efalizumab treatment of psoriasis vulgaris: a cohort study in outpatient clinical practice. <i>Clinical and Experimental Dermatology</i> , 2009, 34, 469-475.	1.3	15
237	Shortcomings of PASI75 and practical calculation of PASI area component. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 180-181.	1.2	15
238	Allergic contact dermatitis to silver in a patient treated with silver sulphadiazine after a burn. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 365-366.	2.4	15
239	Sequential paradoxical psoriasiform reaction and sacroiliitis following adalimumab treatment of hidradenitis suppurativa, successfully treated with guselkumab. <i>Dermatologic Therapy</i> , 2020, 33, e14180.	1.7	15
240	Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials. <i>Advances in Therapy</i> , 2022, 39, 2862-2872.	2.9	15
241	Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational <i>psoriasis study of health outcomes</i> (<scp>PSoHO</scp>). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 2087-2100.	2.4	15
242	Interleukin-1 Increases 15-Hydroxyeicosatetraenoic Acid Production in Human Dermal Fibroblasts. <i>Journal of Investigative Dermatology</i> , 1994, 102, 98-104.	0.7	14
243	Congenital Acantholytic Dyskeratotic Dermatitis: Localized Darier Disease or Disseminated Benign Papular Acantholytic Dermatitis?. <i>Pediatric Dermatology</i> , 2003, 20, 262-265.	0.9	14
244	Spanish Evidence-Based Guidelines on the Treatment of Moderate to Severe Psoriasis with Biologic Agents. <i>Actas Dermo-sifiliográficas</i> , 2009, 100, 386-413.	0.4	14
245	Recommendations for the Coordinated Management of Psoriatic Arthritis by Rheumatologists and Dermatologists: A Delphi Study. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 216-232.	0.4	14
246	Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1405-1409.	1.2	14
247	Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 450-457.	2.4	14
248	Psoriasis ungueal. <i>Actas Dermo-sifiliográficas</i> , 2022, 113, 481-490.	0.4	14
249	Immunohistochemical Detection of Bcl-2 in Kaposi's Sarcoma Lesions Varies According to Histopathologic Stage, Whereas Expression of Bcl-x and Mcl-1 Differs According to Human Immunodeficiency Virus Serologic Status of Patients. <i>Modern Pathology</i> , 2000, 13, 438-445.	5.5	13
250	Cutaneous angiolymphoid hyperplasia with high endothelial venules is characterized by endothelial expression of cutaneous lymphocyte antigen. <i>Human Pathology</i> , 2001, 32, 227-229.	2.0	13
251	Keratosis lichenoides chronica. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2001, 15, 84-85.	2.4	13
252	Tratamiento de la psoriasis del cuero cabelludo. Revisión de la evidencia y Consenso Delphi del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología. <i>Actas Dermo-sifiliográficas</i> , 2010, 101, 827-846.	0.4	13

#	ARTICLE	IF	CITATIONS
253	Efficacy and Safety of Clinical Use of Etanercept for the Treatment of Moderate-to-Severe Psoriasis in Spain: Results of a Multicentric Prospective Study at 12 Months Follow-Up. <i>Dermatology</i> , 2012, 225, 220-230.	2.1	13
254	Pseudocystic Encapsulation: A Late Noninflammatory Complication of Hyaluronic Acid Filler Injections. <i>Dermatologic Surgery</i> , 2013, 39, 1726-1728.	0.8	13
255	Mohs micrographic surgery for basal cell carcinomas: results of a Spanish retrospective study and Kaplan-Meier survival analysis of tumour recurrence. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1363-1369.	2.4	13
256	Crusted (Norwegian) scabies: an under-recognized infestation characterized by an atypical presentation and delayed diagnosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 483-485.	2.4	13
257	The interleukin-1 family cytokines in psoriasis: pathogenetic role and therapeutic perspectives. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 187-199.	3.0	13
258	Pityriasis lichenoides chronica induced by infliximab, with response to methotrexate. <i>European Journal of Dermatology</i> , 2010, 20, 511-512.	0.6	13
259	Multiple minute digitate hyperkeratosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2002, 16, 422-424.	2.4	12
260	Pigmented Paget's disease in a man previously treated with mammoplasty reduction for gynecomastia. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, S62-S63.	1.2	12
261	Induction phase, primary endpoint, time to decide on primary failure, and therapeutic goals in biologic treatment of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e257-60.	2.4	12
262	Evidence-Based Guidelines of the Spanish Psoriasis Group on the Use of Biologic Therapy in Patients With Psoriasis in Difficult-to-Treat Sites (Nails, Scalp, Palms, and Soles). <i>Actas Dermosifiliográficas</i> , 2014, 105, 923-934.	0.4	12
263	Metabolic syndrome in Spanish patients with psoriasis needing systemic therapy: Prevalence and association with cardiovascular disease in PSO-RISK, a cross-sectional study. <i>Journal of Dermatological Treatment</i> , 2015, 26, 318-325.	2.2	12
264	Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 294-303.	2.4	12
265	Guselkumab for the treatment of adults with moderate to severe plaque psoriasis. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 589-597.	3.0	12
266	The safety of ixekizumab in psoriasis drug therapy. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 117-130.	2.4	12
267	Overexpression of p53 in disseminated superficial actinic porokeratosis with and without malignant degeneration. <i>Archives of Dermatology</i> , 1995, 131, 353-354.	1.4	12
268	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. <i>JAMA Dermatology</i> , 2022, 158, 561.	4.1	12
269	Metabolism of exogenous arachidonic acid by polymorphonuclear leukocytes from psoriatic patients. <i>Archives of Dermatological Research</i> , 1991, 283, 77-80.	1.9	11
270	Mycosis fungoides associated with unusual epidermal hyperplasia. <i>Clinical and Experimental Dermatology</i> , 1996, 21, 61-64.	1.3	11

#	ARTICLE	IF	CITATIONS
271	Lipodystrophia Centrifugalis Abdominalis Infantilis: A Case Report. <i>Pediatric Dermatology</i> , 1997, 14, 216-218.	0.9	11
272	Calcinosis Cutis Following Calcium Chloride Electrode Paste Application for Auditoryâ€Brainstem Evoked Potentials Recording. <i>Pediatric Dermatology</i> , 1998, 15, 27-30.	0.9	11
273	Consensus Document on the Evaluation and Treatment of Moderate to Severe Psoriasis. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2009, 100, 277-288.	0.4	11
274	EADV preceptorship: advances in dermatology. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 2-24.	2.4	11
275	Cardiovascular Risk and Psoriasis: the Role of Biologic Therapy. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2012, 103, 853-862.	0.4	11
276	Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials. <i>Journal of Rheumatology</i> , 2019, 46, 1458-1461.	2.0	11
277	Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study. <i>Journal of Dermatological Treatment</i> , 2020, 31, 344-351.	2.2	11
278	Guselkumab in the treatment of moderate-to-severe plaque psoriasis. <i>Immunotherapy</i> , 2020, 12, 355-371.	2.0	11
279	Definition of minimal disease activity in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 422-430.	2.4	11
280	Confluent and reticulated papillomatosis of Gougerot and Carteaud: minocycline deserves trial before etretinate. <i>Archives of Dermatology</i> , 1995, 131, 109-110.	1.4	11
281	Desarrollo y validaciÃ³n preliminar del instrumento HSQoL-24 para evaluar calidad de vida en pacientes con hidradenitis supurativa. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2019, 110, 554-560.	0.4	11
282	Vaccine hesitancy and access to psoriasis care during the <scp>COVID</scp> â€19 pandemic: findings from a global patientâ€reported crossâ€sectional survey. <i>British Journal of Dermatology</i> , 2022, 187, 254-256.	1.5	11
283	Petechial glove and sock syndrome caused by parvovirus B19. <i>Cutis</i> , 1994, 54, 335-40.	0.3	11
284	Acquired Pachydermatoglyphy A Cutaneous Sign of Internal Malignancy. <i>International Journal of Dermatology</i> , 1988, 27, 688-689.	1.0	10
285	The New Labcor-Santiago Pericardial Bioprosthesis. <i>Journal of Cardiac Surgery</i> , 1991, 6, 613-619.	0.7	10
286	Enhancement of PUVA Phototoxic Effects Following Celery Ingestion: Cool Broth Also Can Burn. <i>Archives of Dermatology</i> , 1994, 130, 809.	1.4	10
287	Decreased immunoreactivity for cell-cycle regulator p27Kip1 in Kaposi's sarcoma correlates with higher stage and extracutaneous involvement. <i>Journal of Pathology</i> , 2000, 191, 387-393.	4.5	10
288	Blepharochalasia and double lip: diagnosis and treatment of Ascher's syndrome. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006, 20, 1390-1391.	2.4	10

#	ARTICLE	IF	CITATIONS
289	Granulomatous septal panniculitis associated with capecitabine (Xeloda®). Journal of the European Academy of Dermatology and Venereology, 2008, 22, 121-122.	2.4	10
290	Eccrine Squamous Syringometaplasia Secondary to Pegylated Liposomal Doxorubicin. Archives of Dermatology, 2008, 144, 1402-3.	1.4	10
291	Identifying the biologic closest to the ideal to treat chronic plaque psoriasis in different clinical scenarios: using a pilot multi-attribute decision model as a decision-support aid. Current Medical Research and Opinion, 2009, 25, 2835-2843.	1.9	10
292	Condrodermatitis nodularis helicis tratada con Óxito con nitroglicerina al 2% en gel. Actas Dermo-sifiliogrÁficas, 2013, 104, 531-532.	0.4	10
293	Informe de expertos en psoriasis: opini3n de los dermat3logos espa±oles sobre el manejo de la psoriasis moderada-grave con agentes biol3gicos en pacientes adultos. Actas Dermo-sifiliogrÁficas, 2013, 104, 400-408.	0.4	10
294	Biosimilares en dermatologÁa. Situaci3n actual (parte I). Actas Dermo-sifiliogrÁficas, 2015, 106, 545-549.	0.4	10
295	A European subset analysis from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis shows country-specific features: results from psoriasis patients in Spain. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1176-1182.	2.4	10
296	Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations. British Journal of Dermatology, 2017, 177, 587-590.	1.5	10
297	High Levels of Platelet-Lymphocyte Complexes in Patients with Psoriasis Are Associated with a Better Response to Anti-TNF Therapy. Journal of Investigative Dermatology, 2020, 140, 1176-1183.	0.7	10
298	Vaccinations in Patients Receiving Systemic Drugs for Skin Disorders: What Can We Learn for SARS-Cov-2 Vaccination Strategies?. Drugs in R and D, 2021, 21, 341-350.	2.2	10
299	Enhancement of PUVA phototoxic effects following celery ingestion: cool broth also can burn. Archives of Dermatology, 1994, 130, 809-810.	1.4	10
300	Granulation Tissue Proliferation During Isotretinoin Treatment. International Journal of Dermatology, 1986, 25, 191-195.	1.0	9
301	Impacto en la calidad de vida relacionada con la salud de pacientes con psoriasis activa y estable. Estudio PSO-LIFE. Actas Dermo-sifiliogrÁficas, 2013, 104, 685-693.	0.4	9
302	Cera para huesos en la cirugÁa dermatol3gica. Actas Dermo-sifiliogrÁficas, 2013, 104, 299-303.	0.4	9
303	Validation of the Spanish Acne Severity Scale (Escala de Gravedad del Acn3 © Espa±ola EGAE). European Journal of Dermatology, 2013, 23, 233-240.	0.6	9
304	Improving patient outcomes in psoriasis: strategies to ensure treatment adherence. Psoriasis: Targets and Therapy, 2015, 5, 109.	2.2	9
305	Immune-Mediated Inflammatory Diseases and Other Comorbidities in Patients With Psoriasis: Baseline Characteristics of Patients in the AQUILES Study. Actas Dermo-sifiliogrÁficas, 2015, 106, 35-43.	0.4	9
306	The depth of follicular extension in actinic keratosis correlates with the depth of invasion in squamous cell carcinoma: implication for clinical treatment. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1657-1661.	2.4	9

#	ARTICLE	IF	CITATIONS
307	Recomendaciones del Grupo de Psoriasis de la AEDV sobre el manejo de la consulta de psoriasis durante la pandemia por COVID-19. <i>Actas Dermo-sifiliográficas</i> , 2020, 111, 802-804.	0.4	9
308	The Role of Epithelial-to-Mesenchymal Transition in Cutaneous Squamous Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2020, 21, 47.	3.0	9
309	Inhibidores de JAK: usos en dermatología. Parte 2: aplicaciones en psoriasis, dermatitis atópica y otras dermatosis. <i>Actas Dermo-sifiliográficas</i> , 2021, 112, 586-600.	0.4	9
310	Autochthonous and imported tegumentary leishmaniasis in Catalonia (Spain): Aetiological evolution in the last four decades and usefulness of different typing approaches based on biochemical, molecular and proteomic markers. <i>Transboundary and Emerging Diseases</i> , 2022, 69, 1404-1418.	3.0	9
311	Artritis psoriásica. <i>Medicina Clínica</i> , 2022, 159, 40-46.	0.6	9
312	Erythema Multiformlike Reaction Caused by Topical Application of Thuja Essential Oil. <i>American Journal of Contact Dermatitis: Official Journal of the American Contact Dermatitis Society</i> , 1994, 5, 94-97.	0.4	8
313	Comentarios a las directrices europeas y británicas sobre el tratamiento de la psoriasis. <i>Actas Dermo-sifiliográficas</i> , 2010, 101, 285-290.	0.4	8
314	Dose escalation may be effective in patients with psoriasis after treatment failure or suboptimal response, but switching to adalimumab is the most cost-effective measure in different scenarios. <i>British Journal of Dermatology</i> , 2013, 168, 674-676.	1.5	8
315	Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis. <i>British Journal of Dermatology</i> , 2018, 178, 1297-1307.	1.5	8
316	Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1214-1223.	2.4	8
317	Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study. <i>Journal of Dermatological Treatment</i> , 2020, 31, 222-226.	2.2	8
318	Biosimilares en el tratamiento de la psoriasis. Actualización. <i>Actas Dermo-sifiliográficas</i> , 2020, 111, 809-814.	0.4	8
319	Good response to pulsed dye laser in patients with capillary malformation-caroteno-vascular malformation syndrome (CM-AVM). <i>Pediatric Dermatology</i> , 2020, 37, 342-344.	0.9	8
320	Safety of calcipotriene and betamethasone dipropionate foam for the treatment of psoriasis. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 423-432.	2.4	8
321	Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses. <i>Actas Dermo-sifiliográficas</i> , 2021, 112, 586-586.	0.4	8
322	Factitial dermatosis of the breast: a possible dermatologic manifestation of Munchausen's syndrome. <i>Cutis</i> , 1989, 44, 292-4.	0.3	8
323	Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE 2 and 3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1275-1283.	2.4	8
324	Absence of Fas (CD95) and FasL (CD95L) immunohistochemical expression suggests Fas/FasL-mediated apoptotic signal is not relevant in cutaneous Kaposi's sarcoma lesions. <i>Journal of Cutaneous Pathology</i> , 1999, 26, 417-423.	1.3	7

#	ARTICLE	IF	CITATIONS
325	National and multinational guidelines in Europe: results from an online survey on awareness of different national and European psoriasis guidelines. Archives of Dermatological Research, 2013, 305, 637-643.	1.9	7
326	Análisis de coste-eficacia incremental de los tratamientos biológicos para la psoriasis en los momentos de valoración significativos para la práctica clínica. Actas Dermo-sifiliográficas, 2014, 105, 951-953.	0.4	7
327	Unidades multidisciplinares de artritis psoriásica: sobre objetivos y modelos. Actas Dermo-sifiliográficas, 2014, 105, 325-327.	0.4	7
328	Modelo de eficiencia de los fármacos biológicos en el tratamiento de la psoriasis moderada-grave durante un año en las condiciones de uso en España. Actas Dermo-sifiliográficas, 2016, 107, 34-43.	0.4	7
329	Malformación glomovenosa congénita en placas: 11 años de seguimiento y respuesta al tratamiento con láser combinado PDL/Nd: YAG. Actas Dermo-sifiliográficas, 2017, 108, 72-74.	0.4	7
330	Actualización del tratamiento tópico en psoriasis: aportación de la combinación de calcipotriol y dipropionato de betametasona en espuma. Actas Dermo-sifiliográficas, 2019, 110, 115-123.	0.4	7
331	Clinical and genetic evaluation of six children with diffuse capillary malformation and undergrowth. Pediatric Dermatology, 2020, 37, 833-838.	0.9	7
332	Response of pityriasis rubra pilaris to brodalumab after primary failure to ustekinumab. International Journal of Dermatology, 2021, 60, e112-e114.	1.0	7
333	CD44 Distribution in Sweat Gland Tumors Suggests It Has Different Functional Roles in the Various Cell Types. American Journal of Dermatopathology, 1996, 18, 483-489.	0.6	7
334	Sequelae following infantile haemangiomas treated with propranolol. European Journal of Dermatology, 2021, 31, 785-790.	0.6	7
335	Cutaneous adverse effects of biological therapies for psoriasis. European Journal of Dermatology, 2008, 18, 693-9.	0.6	7
336	Erythroderma due to ribostamycin. Contact Dermatitis, 1989, 21, 79-82.	1.4	6
337	Differential expression of c-Met in Kaposi's sarcoma according to progression stage and HIV infection status. Journal of Cutaneous Pathology, 1999, 26, 227-231.	1.3	6
338	Treatment of Scalp Psoriasis: Review of the Evidence and Delphi Consensus of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermo-sifiliográficas, 2010, 101, 827-846.	0.4	6
339	Artritis psoriásica: lo que el dermatólogo debe saber (Parte 1). Actas Dermo-sifiliográficas, 2010, 101, 578-584.	0.4	6
340	Periungual Acral Fibrokeratoma: Surgical Excision Using a Banner Flap. Actas Dermo-sifiliográficas, 2013, 104, 830-832.	0.4	6
341	Biosimilares en dermatología: infliximab para empezar. Actas Dermo-sifiliográficas, 2013, 104, 175-180.	0.4	6
342	Leishmaniasis cutánea en un paciente con artritis psoriásica tratado con infliximab: tratamiento con crioterapia y Glucantime® intralesional. Actas Dermo-sifiliográficas, 2014, 105, 714-716.	0.4	6

#	ARTICLE	IF	CITATIONS
343	Serum C-reactive protein in patients undergoing elective shoulder arthroplasty. Prospective study. <i>Journal of Orthopaedic Science</i> , 2017, 22, 858-861.	1.1	6
344	Lower lip capillary malformation associated with lymphatic malformation without overgrowth: Part of the spectrum of <sc>CLAPO</sc> syndrome. <i>Pediatric Dermatology</i> , 2018, 35, e243-e244.	0.9	6
345	Biosimilars for Psoriasis "Experience from Europe. <i>Current Dermatology Reports</i> , 2019, 8, 26-34.	2.1	6
346	Vemurafenib-induced histiocytoid neutrophilic panniculitis simulating myeloid leukaemia cutis. <i>Cancer Biology and Therapy</i> , 2019, 20, 237-239.	3.4	6
347	Occupational allergic contact dermatitis to isobornyl acrylate present in cell phone screen protectors. <i>Contact Dermatitis</i> , 2021, 84, 352-354.	1.4	6
348	Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 797-806.	2.4	6
349	Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE€2 and AMAGINE€3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2034-2044.	2.4	6
350	Adherence to a reliable PJI diagnostic protocol minimizes unsuspected positive cultures rate. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 653.	1.9	6
351	A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence. <i>International Journal of Clinical Pharmacy</i> , 2022, 44, 725-730.	2.1	6
352	Fibroqueratoma acral periungueal: exÃ©resis quirÃ©rgica en bandera. <i>Actas Dermo-sifiligrÃ©ficas</i> , 2013, 104, 830-832.	0.4	5
353	Biosimilars in Dermatology: Starting With Infliximab. <i>Actas Dermo-sifiligrÃ©ficas</i> , 2013, 104, 175-180.	0.4	5
354	Implementing therapeutic goals in maintenance treatment of psoriasis with biologics: adalimumab can be more cost-effective than infliximab or ustekinumab in real life. <i>European Journal of Dermatology</i> , 2013, 23, 407-408.	0.6	5
355	Predictors of biologic treatment of psoriasis: a non-interventional study. <i>ClinicoEconomics and Outcomes Research</i> , 2014, 6, 93.	1.9	5
356	Anetodermia primaria asociada a sÃ©ndrome de SjÃ©gren primario y anticuerpos anticardiolipina. <i>Actas Dermo-sifiligrÃ©ficas</i> , 2014, 105, 99-101.	0.4	5
357	Los tratamientos biolÃ³gicos de la psoriasis moderada a grave no son alternativas terapÃ©uticas equivalentes. <i>Actas Dermo-sifiligrÃ©ficas</i> , 2014, 105, 483-486.	0.4	5
358	Biosimilars in Dermatology: Current Situation (Part II). <i>Actas Dermo-sifiligrÃ©ficas</i> , 2015, 106, 550-554.	0.4	5
359	Biosimilares en dermatologÃ­a. SituaciÃ³n actual (parte ii). <i>Actas Dermo-sifiligrÃ©ficas</i> , 2015, 106, 550-554.	0.4	5
360	Infantile hemangiomas with minimal or arrested growth associated with soft tissue hypertrophy: a case series of 10 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1924-1929.	2.4	5

#	ARTICLE	IF	CITATIONS
361	Novel clinical and molecular findings in Spanish patients with naevoid basal cell carcinoma syndrome. <i>British Journal of Dermatology</i> , 2018, 178, 198-206.	1.5	5
362	Incidence of cardiovascular events among tildrakizumab-treated patients with moderate-to-severe plaque psoriasis: pooled data from three large randomised clinical trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e21-e24.	2.4	5
363	Informes de posicionamiento terapéutico: utilidad y transparencia. <i>Actas Dermo-sifiliográficas</i> , 2020, 111, 3-6.	0.4	5
364	Follmann Balanitis: An Atypical Form of Primary Cutaneous Syphilis. <i>JAMA Dermatology</i> , 2020, 156, 1012.	4.1	5
365	Sonication in shoulder surgery: is it necessary?. <i>International Orthopaedics</i> , 2020, 44, 1755-1759.	1.9	5
366	IL-13 antagonists in the treatment of atopic dermatitis. <i>Immunotherapy</i> , 2021, 13, 327-344.	2.0	5
367	Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2094-2101.	2.2	5
368	Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model. <i>Dermatology and Therapy</i> , 2021, 11, 1291-1304.	3.0	5
369	Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab. <i>Dermatology and Therapy</i> , 2021, 11, 1265-1275.	3.0	5
370	Detection of antineutrophil cytoplasmic antibodies in patients with hepatitis C virus-induced cutaneous vasculitis with mixed cryoglobulinemia. <i>Archives of Dermatology</i> , 1996, 132, 974-975.	1.4	5
371	Oral ulcers in heart transplant patient. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2018, 84, 750.	0.6	5
372	An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00344.	1.3	5
373	Early Treatment Targets for Predicting Long-term Dermatology Life Quality Index Response in Patients with Moderate-to-Severe Plaque Psoriasis: A Analysis from a Long-term Clinical Study. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2020, 13, 18-22.	0.1	5
374	The impact of achieving and maintaining near-complete or complete skin clearance on patient quality of life in moderate-to-severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 169-172.	1.2	5
375	Gastric adenocarcinoma in a patient with zeroderma pigmentosum. <i>British Journal of Dermatology</i> , 1985, 113, 632-633.	1.5	4
376	Artritis psoriásica. Lo que el dermatólogo debe saber (Parte 2). <i>Actas Dermo-sifiliográficas</i> , 2010, 101, 742-748.	0.4	4
377	Narrowband UV-B, Monochromatic Excimer Laser, and Photodynamic Therapy in Psoriasis: A Consensus Statement of the Spanish Psoriasis Group. <i>Actas Dermo-sifiliográficas</i> , 2011, 102, 175-186.	0.4	4
378	Cardiovascular risk factors and cardiovascular diseases in patients with moderate to severe psoriasis under systemic treatment. PSO-RISK, descriptive study. <i>European Journal of Dermatology</i> , 2014, 24, 662-669.	0.6	4

#	ARTICLE	IF	CITATIONS
379	PÃnfigo herpetiforme con evoluciÃn a pÃnfigo foliÃceo. DescripciÃn de un caso. Actas Dermo-sifiliogrÃficas, 2014, 105, 526-528.	0.4	4
380	Multidisciplinary Teams for Psoriatic Arthritis: On Aims and Approaches. Actas Dermo-sifiliogrÃficas, 2014, 105, 325-327.	0.4	4
381	Epidermolytic Hyperkeratosis. American Journal of Dermatopathology, 2015, 37, 734-735.	0.6	4
382	Etanercept en el tratamiento de la artritis psoriÃsica. Actas Dermo-sifiliogrÃficas, 2015, 106, 252-259.	0.4	4
383	Hidradenitis supurativa: nuevas oportunidades para una enfermedad dermatolÃgica huÃrfana. Actas Dermo-sifiliogrÃficas, 2015, 106, 448-451.	0.4	4
384	Monoclonal gammopathy of undetermined significance (<sc>MGUS</sc>) in patients with psoriasis may be associated with long-term treatment with efalizumab, but not with anti-TNF treatments or ustekinumab. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 609-611.	2.4	4
385	Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2. Journal of Dermatological Treatment, 2021, 32, 484-491.	2.2	4
386	A case report of PHF6 mosaicism: Beyond the classic BÃrjeson-Forsman-Lehmann syndrome. Pediatric Dermatology, 2021, 38, 919-925.	0.9	4
387	Carga de la psoriasis en CataluÃa: datos epidemiolÃgicos, comorbilidades asociadas, uso de recursos sanitarios e incapacidad laboral. Actas Dermo-sifiliogrÃficas, 2021, 112, 425-433.	0.4	4
388	MicroRNA31 and MMP-1 contribute to the differentiated pathway of invasion -with enhanced epithelial-to-mesenchymal transition- in squamous cell carcinoma of the skin. Archives of Dermatological Research, 2021, , 1.	1.9	4
389	[Translated article] Practical Update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and General Management of Psoriasis With Biologic Therapy. Actas Dermo-sifiliogrÃficas. 2022, 113, T261-T277.	0.4	4
390	[Translated article] Nail Psoriasis. Actas Dermo-sifiliogrÃficas, 2022, 113, T481-T490.	0.4	4
391	Bone Wax in Dermatologic Surgery. Actas Dermo-sifiliogrÃficas, 2013, 104, 299-303.	0.4	3
392	Incremental Cost-Effectiveness Ratio Analysis of Biologic Treatments for Psoriasis at Clinically Significant Evaluation Time Points. Actas Dermo-sifiliogrÃficas, 2014, 105, 951-953.	0.4	3
393	Treatment of Moderate to Severe Plaque Psoriasis With Biologics: Analysis of the Additional Cost of Temporary Dose Escalation vs Switch to Another Biologic After Failure of Maintenance Therapy. Actas Dermo-sifiliogrÃficas, 2014, 105, 401-412.	0.4	3
394	Biosimilares y biolÃgicos de referencia: la intercambiabilidad de los biosimilares requiere la participaciÃn del dermatÃlogo. Actas Dermo-sifiliogrÃficas, 2014, 105, 435-437.	0.4	3
395	Long-term (1 year) efficacy of etanercept in moderate-to-severe psoriasis. Results of a multicentric observational study in Spain. European Journal of Dermatology, 2015, 25, 410-417.	0.6	3
396	Model for Assessing the Efficiency of Biologic Drugs in the Treatment of Moderate to Severe Psoriasis for 1 Year in Clinical Practice in Spain. Actas Dermo-sifiliogrÃficas, 2016, 107, 34-43.	0.4	3

#	ARTICLE	IF	CITATIONS
397	Triple paradoxical reaction due to adalimumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e71-e73.	2.4	3
398	Baños de parafina para el tratamiento del eccema crónico de las manos. <i>Actas Dermo-sifilográficas</i> , 2017, 108, 261-264.	0.4	3
399	Psoriasis: inequality or individualized care?. <i>British Journal of Dermatology</i> , 2017, 176, 1111-1113.	1.5	3
400	Update on Topical Treatments for Psoriasis: The Role of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam. <i>Actas Dermo-sifilográficas</i> , 2019, 110, 115-123.	0.4	3
401	Iceberg sign as a dermoscopic clue of actinic keratosis neglecta. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e254-e256.	2.4	3
402	Satisfactory treatment of mucocutaneous lesions in hereditary hemorrhagic telangiectasia patients with dual pulsed dye laser and neodymium: yttrium-aluminum-garnet. <i>Dermatologic Therapy</i> , 2021, 34, e15124.	1.7	3
403	Análisis del coste incremental por respondedor (PASI75, PASI90 y PASI100) basado en un metaanálisis en red de tratamientos biológicos para la psoriasis: España 2018. <i>Actas Dermo-sifilográficas</i> , 2019, 110, 517-518.	0.4	3
404	Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis Council. <i>JAAD International</i> , 2020, 1, 224-230.	2.2	3
405	Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 941-953.	1.4	3
406	Beyond plaque psoriasis – pathogenesis and treatment of other psoriasis phenotypes. <i>Current Opinion in Rheumatology</i> , 0, Publish Ahead of Print, .	4.3	3
407	KOH Preparation for Early Diagnosis of Systemic Candidiasis in Heroin Addicts. <i>International Journal of Dermatology</i> , 1987, 26, 257-257.	1.0	2
408	Morphological Aspects Sodium lauryl sulfate stimulates the metabolism of endogenous arachidonic acid in epidermal cell suspensions. <i>Contact Dermatitis</i> , 1990, 23, 235-235.	1.4	2
409	Pharmacodynamic interaction with phototoxic plants during PUVA therapy. <i>British Journal of Dermatology</i> , 1997, 136, 973-974.	1.5	2
410	Treatment of severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 17-18.	2.4	2
411	Expert Report on Psoriasis: Spanish Dermatologists' Opinions on the Use of Biologic Agents to Manage Moderate to Severe Psoriasis in Adults. <i>Actas Dermo-sifilográficas</i> , 2013, 104, 400-408.	0.4	2
412	Anti-tumour necrosis factor- treatment and weight gain in psoriasis: the ‘pudgy blanching’ conundrum. <i>British Journal of Dermatology</i> , 2013, 168, 923-924.	1.5	2
413	Psoriasis y embarazo: revisión (II). <i>Actas Dermo-sifilográficas</i> , 2014, 105, 813-821.	0.4	2
414	Impact of Alexithymia and Disease Characteristics on Work Productivity and Activity In Psoriasis Patients With Short Disease Duration: Epidepso Multicentre Study. <i>Value in Health</i> , 2015, 18, A425-A426.	0.3	2

#	ARTICLE	IF	CITATIONS
415	On clinical thresholds, clinical equivalents and indirect comparisons of biological treatments for moderate-to-severe psoriasis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015, 40, 131-134.	1.5	2
416	Chronic Ulceration and Fibrosis of the Forearm. <i>JAMA Dermatology</i> , 2015, 151, 331.	4.1	2
417	Enfermedad inflamatoria intestinal: abordaje conjunto digestivo-dermatológico. <i>Actas Dermo-sifiligráficas</i> , 2017, 108, 184-191.	0.4	2
418	The AGEs of Psoriasis: A Biomarker for Severity and a Pathogenetic Link to Comorbidities. <i>Acta Dermato-Venereologica</i> , 2017, 97, 775.	1.3	2
419	Dystrophic Calcification in a Patient with Primary Localized Cutaneous Nodular Amyloidosis: An Uncommon Ultrasound Finding. <i>Acta Dermato-Venereologica</i> , 2018, 98, 144-145.	1.3	2
420	La efectividad del tratamiento con omalizumab en la vida real es menor en pacientes con urticaria crónica de más de 18 meses de evolución y tratamiento inmunosupresor previo. <i>Actas Dermo-sifiligráficas</i> , 2019, 110, 289-296.	0.4	2
421	Psoriasis precipitated by timolol eye drops. A series of eight cases. <i>Australasian Journal of Dermatology</i> , 2020, 61, e91-e93.	0.7	2
422	Encuesta de opinión a pacientes con psoriasis moderada-grave sobre la persistencia de los tratamientos biológicos. <i>Actas Dermo-sifiligráficas</i> , 2020, 111, 691-694.	0.4	2
423	Mycosis fungoides associated with unusual epidermal hyperplasia. <i>Clinical and Experimental Dermatology</i> , 1996, 21, 61-64.	1.3	2
424	The role of biologics in the treatment of moderate-to-severe plaque psoriasis. <i>Italian Journal of Dermatology and Venereology</i> , 2016, 152, 28-35.	0.2	2
425	Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial. <i>Vestnik Dermatologii i Venerologii</i> , 2021, 97, 80-91.	0.6	2
426	Mycosis fungoides associated with unusual epidermal hyperplasia. <i>Clinical and Experimental Dermatology</i> , 1996, 21, 61-4.	1.3	2
427	Shear wave elastography as a potential tool for quantitative assessment of sinus tracts fibrosis in hidradenitis suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	2
428	Effect of Lonapalene on Metabolism of Exogenous Arachidonic Acid in Human Platelets. <i>Skin Pharmacology and Physiology</i> , 1989, 2, 86-92.	2.5	1
429	Prevalencia de cicatrices en la población española y su abordaje terapéutico. <i>Piel</i> , 2005, 20, 63-67.	0.0	1
430	Lesiones cutáneas por cupping. <i>Piel</i> , 2005, 20, 481-482.	0.0	1
431	Adams-Oliver Syndrome with Unusual Central Nervous System Alterations. <i>Pediatric Dermatology</i> , 1998, 15, 48-50.	0.9	1
432	Reactions to Infliximab Infusions in Dermatologic Patients: Consensus Statement and Treatment Protocol. <i>Actas Dermo-sifiligráficas</i> , 2009, 100, 103-112.	0.4	1

#	ARTICLE	IF	CITATIONS
433	Actualizaci3n en dermatopatologAa. Actas Dermo-sifiliogrAificas, 2013, 104, 204-211.	0.4	1
434	Psoriasis y su relaci3n con el sAandrome metab3lico. Revista Colombiana De ReumatologAa, 2013, 20, 228-236.	0.1	1
435	The Value of Achieving Complete or Near Complete Resolution of Psoriasis. Value in Health, 2015, 18, A427.	0.3	1
436	Biosimilars in Dermatology: Current Situation (Part I). Actas Dermo-sifiliogrAificas, 2015, 106, 545-549.	0.4	1
437	Etanercept in the Treatment of Psoriatic Arthritis. Actas Dermo-sifiliogrAificas, 2015, 106, 252-259.	0.4	1
438	Biosimilars in psoriasis 2015: what is next?. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 467-469.	2.4	1
439	Psoriasis, artritis psoriAisica y enfermedad de Crohn: circuitos de citocinas y papel de la disbiosis. Actas Dermo-sifiliogrAificas, 2016, 107, 95-97.	0.4	1
440	Choice of first-line biologic therapy in psoriasis: understanding the past and shaping the future?. British Journal of Dermatology, 2017, 177, 623-624.	1.5	1
441	Significant weight loss improves and prevents psoriasis and psoriatic arthritis in obese patients: a Critically Appraised Topic and a call to action. British Journal of Dermatology, 2019, 181, 884-885.	1.5	1
442	Incremental Cost per Responder (PASI-75, PASI-90 and PASI-100) Based on a Network Meta-Analysis of Biologic Therapies for Psoriasis: Spain 2018. Actas Dermo-sifiliogrAificas, 2019, 110, 517-518.	0.4	1
443	Economic Impact of Etanercept in Patients with Psoriasis and Psoriatic Arthritis in Spain: A Systematic Review. Dermatology and Therapy, 2019, 9, 479-496.	3.0	1
444	<i>Saprochaete capitata</i> disseminated infection presenting as macular rash after haematopoietic stem cell transplantation. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e748-e750.	2.4	1
445	MetaanAilisis y comparaciones indirectas. MAtodos y paradigma: tratamiento biol3gico de la psoriasis. Actas Dermo-sifiliogrAificas, 2021, 112, 203-215.	0.4	1
446	LRP1/CD91 is highly expressed in monocytes from patients with vitiligo " even after repigmentation. Experimental Dermatology, 2021, 30, 390-395.	2.9	1
447	Head-to-head comparison of biologics in psoriasis: better acceleration does not necessarily win all races. British Journal of Dermatology, 2021, 184, 992-993.	1.5	1
448	Burden of Psoriasis in Catalonia: Epidemiology, Associated Comorbidities, Health Care Utilization, and Sick Leave. Actas Dermo-sifiliogrAificas, 2021, 112, 425-433.	0.4	1
449	Erythematous plaques with zosteriform distribution in a patient treated with TNF inhibitor adalimumab for psoriasis. International Journal of Dermatology, 2021, 60, 1366-1367.	1.0	1
450	An integrated safety analysis of treatment-emergent fungal infections in patients with psoriasis treated with ixekizumab from 16 clinical studies. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e828-e831.	2.4	1

#	ARTICLE	IF	CITATIONS
451	Nodular scabies mimicking breast cancer skin metastasis. Indian Journal of Dermatology, Venereology and Leprology, 2021, 88, 88-89.	0.6	1
452	Authors'™ reply to Borg and Thoning: "Comment on: "Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study" American Journal of Clinical Dermatology, 2021, 22, 903-904.	6.7	1
453	Retiform purpura in an 80-year-old woman. International Journal of Dermatology, 2022, , .	1.0	1
454	Vulvar allergic contact dermatitis caused by <i>Magnolia officinalis</i> bark extract. Contact Dermatitis, 2022, 87, 96-97.	1.4	1
455	Biosimilars or Follow-on Biologics in Dermatology. Actas Dermo-sifilograficas, 2010, 101, 4-6.	0.4	0
456	Commentary on European and British Guidelines for the Treatment of Psoriasis. Actas Dermo-sifilograficas, 2010, 101, 285-290.	0.4	0
457	Carcinoma epidermoide infiltrante de clitoris en paciente de 30 años, no ligado a infección por virus del papiloma humano. Progresos En Obstetricia Y Ginecologia, 2010, 53, 72-75.	0.0	0
458	Biosimilares o biosecuelas en Dermatología. Actas Dermo-sifilograficas, 2010, 101, 4-6.	0.4	0
459	Clinical Characteristics and Disease Course in Patients Treated With Efalizumab Following Suspension of Marketing Authorization by the European Medicines Agency: A Multicenter Observational Study. Actas Dermo-sifilograficas, 2011, 102, 354-364.	0.4	0
460	Uso de biológicos en la psoriasis durante el embarazo. Piel, 2011, 26, 40-45.	0.0	0
461	Respuesta a: Sobre las ecuaciones para estimar el riesgo vascular en pacientes con psoriasis (REGICOR y Tj ETQq1 0.784314 rgBT / Ov 0.4)	0.4	0
462	Response to: "On Cardiovascular Risk Estimation in Patients With Psoriasis: The REGICOR and SCORE Scales" Actas Dermo-sifilograficas, 2012, 103, 943-944.	0.4	0
463	Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: The VACAP study. Actas Dermo-sifilograficas, 2013, 104, 807-814.	0.4	0
464	SAT0018...Identification of new epistatic interactions with the HLA region in the genetic etiology of psoriasis and psoriatic arthritis. Annals of the Rheumatic Diseases, 2013, 71, 477.1-477.	0.9	0
465	AB0017...Association study of genetic risk variants for psoriasis in a large cohort of psoriatic arthritis, psoriasis and controls of the spanish population and association with relevant clinical subphenotypes. Annals of the Rheumatic Diseases, 2013, 71, 638.4-638.	0.9	0
466	Biosimilars and Reference Biologics: Decisions on Biosimilar Interchangeability Require the Involvement of Dermatologists. Actas Dermo-sifilograficas, 2014, 105, 435-437.	0.4	0
467	IL-17 in psoriasis. The final frontier or just another brick in the wall?. Actas Dermo-sifilograficas, 2014, 105, 6-8.	0.4	0
468	Therapeutic implications of IL-17A blockade in psoriasis. Actas Dermo-sifilograficas, 2014, 105, 1-5.	0.4	0

#	ARTICLE	IF	CITATIONS
469	Psoriasis In Pregnancy: A Review (II). Actas Dermo-sifiligráficas, 2014, 105, 813-821.	0.4	0
470	Real World Skin Clearance Rates for Biologic Treatments In Patients With Moderate to Severe Plaque Psoriasis: Interim Results From A Large Prospective, Observational Study. Value in Health, 2015, 18, A429.	0.3	0
471	Defining effective approaches to the reduction or elimination of biologic therapy immunogenicity and loss of response. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 321-323.	2.4	0
472	Interleukin-17 in skin: psoriasis and yonder. British Journal of Dermatology, 2016, 175, 859-860.	1.5	0
473	Cytokine Pathways and the Role of Dysbiosis in Psoriasis, Psoriatic Arthritis, and Crohn Disease. Actas Dermo-sifiligráficas, 2016, 107, 95-97.	0.4	0
474	Inflammatory Bowel Disease: Joint Management in Gastroenterology and Dermatology. Actas Dermo-sifiligráficas, 2017, 108, 184-191.	0.4	0
475	Registries and biologics: disease populations matter. British Journal of Dermatology, 2017, 176, 567-568.	1.5	0
476	Merece la pena hacerse miembro de la European Academy of Dermatology and Venereology (EADV). Actas Dermo-sifiligráficas, 2017, 108, 605.	0.4	0
477	Líneas de demarcación pigmentarias tipo B en gestante. Actas Dermo-sifiligráficas, 2018, 109, 446.	0.4	0
478	Sesgo en el Cuestionario de productividad laboral y deterioro de las actividades: psoriasis (WPAI:PSO) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.4	0
479	Patient-Reported Outcomes in Psoriasis Validated in Spain: PROs and Cons. Actas Dermo-sifiligráficas, 2019, 110, 518-519.	0.4	0
480	British Association of Dermatologists Biologic Interventions Register delivers: infliximab increases risk of serious infections. British Journal of Dermatology, 2019, 180, 257-258.	1.5	0
481	Milia, una reacción infrecuente tras terapia fotodinámica. Actas Dermo-sifiligráficas, 2019, 110, 71-74.	0.4	0
482	Psoriasis Area and Severity Index vs. pharmacokinetics: can monitoring 4-week postinjection ustekinumab concentrations in patients with suboptimal response be clinically relevant?. British Journal of Dermatology, 2020, 182, 271-272.	1.5	0
483	Biosimilars in the Treatment of Psoriasis: An Update. Actas Dermo-sifiligráficas, 2020, 111, 809-814.	0.4	0
484	Opinion Survey on Persistence of Biologic Therapies in Patients with Moderate to Severe Psoriasis. Actas Dermo-sifiligráficas, 2020, 111, 691-694.	0.4	0
485	Asymptomatic Exophytic Plaques on the Penis of a Patient With HIV Infection: Answer. American Journal of Dermatopathology, 2020, 42, 218-219.	0.6	0
486	Asymptomatic Exophytic Plaques on the Penis of a Patient With HIV Infection: Challenge. American Journal of Dermatopathology, 2020, 42, e28-e29.	0.6	0

#	ARTICLE	IF	CITATIONS
487	Purple ulcerated nodules in a middle-aged man. International Journal of Dermatology, 2020, 59, e96-e98.	1.0	0
488	An atypical and infrequent palmoplantar affection. International Journal of Dermatology, 2021, 60, 703-704.	1.0	0
489	Grover Disease with Focus on New Histopathological Patterns. , 2021, , 121-130.		0
490	Meta-analysis and Indirect Comparisons: on Methods, Paradigms, and Biologic Treatments for Psoriasis. Actas Dermo-sifiliográficas, 2021, 112, 203-215.	0.4	0
491	Pinch grafting: a unique application?. Journal of Wound Care, 2021, 30, 504-505.	1.2	0
492	Comment on "An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology". Journal of the American Academy of Dermatology, 2021, 85, e89-e90.	1.2	0
493	Prepubertal retroareolar cysts. Pediatric Dermatology, 2021, 38, 1368-1369.	0.9	0
494	Patient reported outcomes en psoriasis validados en España: PROs y contras. Actas Dermo-sifiliográficas, 2019, 110, 518-519.	0.4	0
495	Carcinoma en coraza. Actas Dermo-sifiliográficas, 2019, 110, e2.	0.4	0
496	Spongiotic and Psoriasiform Dermatitis. , 2020, , 5-40.		0
497	Clinical and ultrasonography follow-up of five cases of calcinosis cutis successfully treated with intralesional sodium thiosulfate. Journal of Ultrasound, 2022, , 1.	1.3	0